A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorAktis Oncology, Inc.

About this trial

This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with B7-H3 imaging positive solid tumors.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years

Histologic or cytologic confirmation of locally advanced or metastatic NSCLC, ES-SCLC, HNSCC, ESCC, CRC or prostatic adenocarcinoma

Radiologic confirmation on CT of at least one measurable tumor lesion per RECIST v1.1

ECOG Performance Status of 0 or 1

Disqualifiers

Prior treatment with a B7-H3 targeted therapy

Prior treatment with a targeted radiotherapy

Received an investigational agent within the previous 28 days

Prior treatment with a cytotoxic chemotherapy, targeted therapy, biologic agent, immunotherapy or external-beam radiotherapy within the previous 28 days

Trial design

Design model

Single group

Treatments tested in this trial

  • [225Ac]Ac-AKY-2519 (therapeutic)

    Drug

    \[225Ac\]Ac-AKY-2519 Injection

  • [64Cu]Cu-AKY-2519 (imaging)

    Drug

    \[64Cu\]Cu-AKY-2519 Injection

Treatment groups

152 Participants
are divided into 1 treatment group
Group A: [225Ac]Ac-AKY-2519Experimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Part 1: Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519

An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of patients experiencing an AE and the number of patients experiencing an SAE will be reported.

Time frame
Up to 30 days following last administration of [225Ac]Ac-AKY-2519
2

Part 1: Occurrence of dose-limiting toxicity (DLT) in participants

Dose-limiting toxicities (DLTs) is defined as any predefined AE occurring during the DLT observation period, except those that are clearly and incontrovertibly due to extraneous circumstances. The number of patients who experience a DLT will be reported separately for each cohort and by dose level within each cohort

Time frame
From first administration of [225Ac]Ac-AKY-2519 to the end of Cycle 1 (each cycle is 28 days)
3

Part 2: Objective Response Rate (ORR)

Part 2: Objective Response Rate (ORR) • Objective response rate is defined as the percentage of patients who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), as determined by the investigator based on RECIST v1.1. Up to 30 days following last administration of \[225Ac\]Ac-AKY-2519

Time frame
Up to 30 days following last administration of [225Ac]Ac-AKY-2519

Secondary outcomes

1

Part 1: Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [64Cu]Cu AKY 2519

An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of patients experiencing an AE will be reported.

Time frame
Up to 6 days following last administration of [64Cu]Cu AKY 2519 or, if earlier, until the first dose of [225Ac]Ac-AKY-2519
2

Part 1: Objective Response Rate (ORR)

ORR is defined as the percentage of patients who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), as determined by the investigator based on RECIST v1.1 or PCWG3-modified RECIST v1.1.

Time frame
Up to 30 days following last administration of [225Ac]Ac-AKY-2519
3

Part 2: Duration of Response (DoR)

Duration of Response (DoR) is defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause.

Time frame
Up to 5 years after first administration
4

Part 2: Progression-Free Survival (PFS)

PFS is defined as the time from treatment initiation to the first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurs first.

Time frame
Up to 5 years after first administration

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.